Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blinded, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA Vaccine Against COVID-19.
Conditions
Interventions
SCTV01C
Placebo
Locations
1
United Arab Emirates
Al Kuwait Hospital (Al Baraha Hospital)
Dubai, United Arab Emirates
Start Date
December 22, 2021
Primary Completion Date
June 1, 2022
Completion Date
January 1, 2023
Last Updated
January 25, 2022
NCT07221162
NCT06082518
NCT06631287
NCT05141058
NCT06679140
NCT06417762
Lead Sponsor
Sinocelltech Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions